RESUMO
The human immunodeficiency virus (HIV) has been reported to target noninfected CD4 and CD8 cells for destruction. This effect is manifested in part through up-regulation of the death receptor Fas ligand (FasL) by HIV-1 negative factor (Nef), leading to bystander damage. However, the signal transduction and transcriptional regulation of this process remains elusive. Here, we provide evidence that p38 mitogen-activated protein kinase (MAPK) is required for this process. Loss-of-function experiments through dominant-negative p38 isoform, p38 siRNA, and chemical inhibitors of p38 activation suggest that p38 is necessary for Nef-induced activator protein-1 (AP-1) activation, as inhibition leads to an attenuation of AP-1-dependent transcription. Furthermore, mutagenesis of the FasL promoter reveals that its AP-1 enhancer element is required for Nef-mediated transcriptional activation. Therefore, a linear pathway for Nef-induced FasL expression that encompasses p38 and AP-1 has been elucidated. Furthermore, chemical inhibition of the p38 pathway attenuates HIV-1-mediated bystander killing of CD8 cells in vitro.
Assuntos
Efeito Espectador , Linfócitos T CD8-Positivos/patologia , Produtos do Gene nef/fisiologia , HIV-1/patogenicidade , Glicoproteínas de Membrana/genética , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo , Linfócitos T CD8-Positivos/virologia , Morte Celular , Células Cultivadas , Elementos Facilitadores Genéticos , Proteína Ligante Fas , Regulação da Expressão Gênica , Humanos , Fator de Transcrição AP-1 , Ativação Transcricional , Produtos do Gene nef do Vírus da Imunodeficiência HumanaRESUMO
OBJECTIVE: To analyze a novel compound, which inhibits serine-threonine protein kinase p38, for its possible bioactivity against HIV-1 infection. METHODS: Proteins involved in cellular signal transduction pathways represent a novel class of host therapeutic targets for infectious diseases. In this regard the serine/threonine kinase p38 MAPK, a member of the mitogen-activated protein (MAP) kinase superfamily of signal transduction molecules may play an important role in HIV-1 infection. We analyzed the ability of this compound (RWJ67657) to inhibit HIV replication in primary T cells and monocytes. Cellular expression of phospho-p38MAPK was studied by Western blot analysis. Blockade of HIV infection induced apoptosis was measured by Annexin V staining. RESULTS: p38 inhibitor RWJ67657 was effective in inhibiting HIV-1 replication in both T-cell and monocyte cell lines, irrespective of the coreceptor used by the virus for entry into the cell. Importantly, both reverse transcriptase and protease resistant escape mutant viruses were effectively suppressed by RWJ67657. In addition, the tested compounds block HIV-induced T-cell apoptosis, a critical means of T-cell depletion linked to AIDS progression. CONCLUSION: Several steps in the HIV-1 virus life cycle appear to depend on cellular activation, including activation of the p38 pathway. Without activation virus replication is thought to be blocked due to incomplete reverse transcription and a lack of proviral DNA integration. The data collectively illustrate that inhibition of the p38 pathway can affect HIV-1 replication. Interruption of HIV infection by p38 inhibitors underscores the value of exploring antiviral drugs that target host cellular proteins.
Assuntos
HIV-1/fisiologia , Imidazóis/farmacologia , Proteínas Quinases Ativadas por Mitógeno/antagonistas & inibidores , Piridinas/farmacologia , Linfócitos T/virologia , Replicação Viral/efeitos dos fármacos , Análise de Variância , Anexina A5/análise , Apoptose , Biomarcadores/análise , Western Blotting/métodos , Linhagem Celular , Farmacorresistência Viral , HIV-1/efeitos dos fármacos , Humanos , Células Jurkat , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Monócitos/enzimologia , Monócitos/patologia , Monócitos/virologia , Fosforilação , Linfócitos T/enzimologia , Linfócitos T/patologia , Células U937 , Proteínas Quinases p38 Ativadas por MitógenoRESUMO
The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-alpha and IL-1 beta. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo.